[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336676-105":59,"doc-detail-336676-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liquid-biopsy-in-the-clinical-management-of-cancers","Liquid Biopsy in the Clinical Management of Cancers","","Liquid biopsy, a noninvasive diagnostic approach that examines circulating tumor components in body fluids, is increasingly used in cancer management. An overview of relevant literature summarizes the current state of clinical applications, including biomarkers such as ctDNA, ctRNA, circulating tumor cells (CTCs), extracellular vesicles (EVs), and other components. The evidence supports uses in early diagnosis, treatment selection, monitoring, and disease assessment across multiple cancer types, including lung, colorectal, breast, and prostate cancers. Advances in NGS and dPCR enable detection of actionable genomic alterations, prediction of treatment response, assessment of minimal residual disease (MRD), and evaluation of tumor heterogeneity, while challenges remain in standardization and clinical integration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsy-in-the-clinical-management-of-cancers/336676/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsy-in-the-clinical-management-of-cancers/336676.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is liquid biopsy used for in cancer management?","Question",{"text":112,"@type":113},"Liquid biopsy supports noninvasive diagnosis by analyzing circulating tumor components, with applications in early cancer detection, treatment selection, monitoring, and disease assessment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers are commonly discussed in the review?",{"text":117,"@type":113},"The review highlights ctDNA, ctRNA, circulating tumor cells (CTCs), extracellular vesicles (EVs), and other liquid-biopsy components that can reflect tumor biology.",{"name":119,"@type":110,"acceptedAnswer":120},"What technologies expand the clinical utility of liquid biopsy?",{"text":121,"@type":113},"Next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) help detect somatic variants and actionable genomic alterations, improving decision-making such as treatment response prediction and MRD monitoring.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336676,1790153420,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nLiquid Biopsy in the Clinical Management of Cancers  \nHo-Yin Ho†, Kei-See (Kasey) Chung†, Chau-Ming Kan and Sze-Chuen (Cesar) Wong *  \nCitation: Ho, H.-Y.; Chung, K.-S.; Kan, C.-M.; Wong, S.-C. Liquid Biopsy in the Clinical Management of Cancers. Int. J. Mol. Sci. 2024, 25, 8594. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25168594](doi.org/10.3390/ijms25168594)  \nAcademic Editor: Shinichi Fukushige  \nReceived: 14 June 2024  \nRevised: 2 August 2024  \nAccepted: 2 August 2024  \nPublished: 6 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University,  \nHong Kong SAR, China; [hoyin.kenny.ho@gmail.com](hoyin.kenny.ho@gmail.com) (H.-Y.H.); [ckskasey@gmail.com](ckskasey@gmail.com) (K.-S.C.);  \n[kantrevor@gmail.com](kantrevor@gmail.com) (C.-M.K.)  \n* Correspondence: [cesar.wong@polyu.edu.hk](cesar.wong@polyu.edu.hk)[ ](cesar.wong@polyu.edu.hk)† These authors contributed equally to this work.  \nAbstract: Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used in cancer management. An overview of relevant literature emphasizes the current state of liquid biopsy applications in cancer care. Biomarkers in liquid biopsy, particularly circulating tumor DNA (ctDNA), circulating tumor RNAs (ctRNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early cancer diagnosis, treatment selection, monitoring, and disease assessment. The implementation of liquid biopsy in precision medicine has shown significant potential in various cancer types, including lung cancer, colorectal cancer, breast cancer, and prostate cancer. Advances in genomic and molecular technologies such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) have expanded the utility of liquid biopsy, enabling the detection of somatic variants and actionable genomic alterations in tumors. Liquid biopsy has also demonstrated utility in predicting treatment responses, monitoring minimal residual disease (MRD), and assessing tumor heterogeneity. Nevertheless, standardizing liquid biopsy techniques, interpreting results, and integrating them into the clinical routine remain as challenges. Despite these challenges, liquid biopsy has significant clinical implications in cancer management, offering a dynamic and noninvasive approach to understanding tumor biology and guiding personalized treatment strategies.  \nKeywords: liquid biopsy; clinical management; cancers  \n1. Introduction  \nCancer is the leading cause of death in the world, accounting for nearly 20 million new cancer cases and 9 .7 million deaths in 2022 . Cancer is also referred to as a silent killer since its symptoms are vague and thus difficult to detect early. Cancer formation consists of the following four phases: initiation, promotion, progression, and metastasis. The first phase, initiation, involves gene variants in a cell. Promotion is the phase between a premalignant lesion and the development of invasive cancer, involving the accumulation of actively proliferating preneoplastic cells. The next phase is progression where genetic and phenotypic changes and cell proliferation occur. At this phase, the tumor size increases rapidly and the cells may undergo further variations with invasive and metastatic potential [1] . The final stage is metastasis, which refers to the spread of cancer cells from a primary tumor to distant organs of the body. The metastasis process is a multistep process, named“metastatic cascade”, broadly divided into five distinct","cbCaioabtSerokm0","https://ap.wps.com/l/cbCaioabtSerokm0","pdf",2274781,27,"English","# Introduction\n## Cancer and metastasis overview\n## Liquid biopsy as a minimally invasive oncology tool","[{\"question\":\"What is liquid biopsy used for in cancer management?\",\"answer\":\"Liquid biopsy supports noninvasive diagnosis by analyzing circulating tumor components, with applications in early cancer detection, treatment selection, monitoring, and disease assessment.\"},{\"question\":\"Which biomarkers are commonly discussed in the review?\",\"answer\":\"The review highlights ctDNA, ctRNA, circulating tumor cells (CTCs), extracellular vesicles (EVs), and other liquid-biopsy components that can reflect tumor biology.\"},{\"question\":\"What technologies expand the clinical utility of liquid biopsy?\",\"answer\":\"Next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) help detect somatic variants and actionable genomic alterations, improving decision-making such as treatment response prediction and MRD monitoring.\"}]","Liquid Biopsy in the Clinical Management of Cancers | PDF",1790016128,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eeaee50daf8dd385b75f9413af55fccb.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee3ae88562b982f1bf51fcbc75d50ee1.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b79d47bef40b6455a5c6dbcb86128cd4.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8eeafdf0315e6fc2391dc035f09c0f3f.webp",980,1385]